

How to Use and Not Abuse MGMA and Other Survey Data in FMV Compliance Programs: Why Flawed Data Usage Leads to Increased Compliance Risk

Timothy R. Smith, Senior Managing Director, Ankura Consulting Group Meghan M. Wong, MS, Assistant Director, Data Solutions, MGMA

Health Care Compliance Association 2017 Compliance Institute March 28, 2017 – National Harbor, MD

General Disclaimer

This program is a general discussion of legal and business issues; it should not be relied upon as legal, valuation, business, financial, or other professional advice.

The panelists will provide their own views and not those of their current or past employers or clients.

Not all slides will be covered in detail. Some are for reference only.

The slides are the result of the collaboration of the panelists and reflect their individual and collective thoughts and observations.

This presentation may include a discussion of hypothetical scenarios. Any hypothetical scenarios are intended to elicit thoughtful and lively discussion, but do not represent actual events.

This program may include a discussion of certain ongoing or settled *qui tam* or other lawsuits. The discussion is based on publicly available documents and allegations in the lawsuits. We wish to remind participants that allegations are allegations only. We also wish to remind participants that the list of cases and related issues we discuss may not be comprehensive.






ANKURA CONSULTING

Session Overview

Part I: Regulatory/Enforcement Context Part II: Examining Industry Usage of Survey Data Part III: The Reality of the Data Part IV: Appropriate Data Use and Solutions Part V: Question and Answer





Regulatory/Enforcement Context

2005 OIG Compliance Guidance.

Is the determination of FMV based upon a **reasonable methodology** that is uniformly applied and properly documented?

Applicable Guidance (From the Stark Commentary).

Phase I (2001) – Flexible Methods: To establish the FMV of a transaction that involves compensation paid for assets or services, we intend to accept any method that is commercially reasonable and provides us with evidence that the compensation is comparable to what is ordinarily paid for an item or service in the location at issue, by parties in arm's-length transactions who are not in a position to refer to one another.

Phase I (2001) – Internal vs. Independent Surveys: We agree that there is no requirement that parties use an independent valuation consultant for any given arrangement when other appropriate valuation methods are available. However, while <u>internally generated surveys</u> can be appropriate as a method of establishing FMV in some circumstances, due to their susceptibility to manipulation and absent independent verification, <u>such surveys do not have strong evidentiary value</u> and, therefore, may be subject to more intensive scrutiny than an independent survey.





Regulatory/Enforcement Context

Applicable Guidance (From the Stark Commentary).

Phase II (2004) - No Bright Line Standard: We appreciate the commenter's desire for clear "bright line" guidance [for determining FMV]. However, **the statute covers such a wide range of potential transactions that it is not possible to verify and list appropriate benchmarks or objective measures for each**. Moreover, the definition of FMV in the statute and regulation is gualified in ways that do not necessarily comport with the usage of the term in standard valuation techniques and methodologies.

<u>Phase III (2007) – Reliance on Salary Surveys</u>: We emphasize, however, that we will continue to scrutinize the FMV of arrangements as FMV is an essential element of many exceptions. <u>Reference to multiple, objective, independently published salary surveys remains a prudent</u> <u>practice for evaluating FMV</u>. Ultimately, the appropriate method for determining FMV for purposes of the physician self-referral law will <u>depend</u> <u>on the nature of the transaction, its location, and other factors</u>.

<u>Phase III (2007) – Burden of Documenting FMV</u>: The statute and regulations provide a definition of FMV for purposes of section 1877 of the Act. <u>The parties to a transaction or an arrangement are in the best position to ensure that the remuneration is at FMV and to document it</u> <u>contemporaneously</u>. If questioned by the government, the burden would be on the parties to explain how the transaction meets the FMV compensation exception requirements.





ecent Enforcement Actions Involving Phy	sician Compensation	
New York Heart Center	\$1.33 million	
Infirmary Health System	\$24.5 million	
All Children's Health System	\$7 million	
Halifax Hospital	\$85 million	
King's Daughters Medical Center	\$40.9 million	
Tuomey Healthcare System	\$72.4 million	
Adventist Health System	\$115 million	
North Broward Hospital District	\$69.5 million	
Columbus Regional Health	\$35 million	
Dr. Andrew Pippas	\$425 thousand	
Westchester Medical Center	\$18.8 million	
Citizens Medical Center	\$21.8 million	

Regulatory/Enforcement Context


Reference to survey data is prominent in enforcement cases


- Government's expert in the Tuomey and Halifax cases
- Tuomey's expert in the *Tuomey* case
- Citizens' Medical Center Case
- Citizens' argued physicians made around national median; thus FMV
- Judge ruled against motion to dismiss, concluding practice losses and pay increases created doubt about FMV, regardless of survey benchmarking
- Benchmarking above 75th and 90th percentiles mentioned frequently in whistleblower complaints as evidence of compensation paid for referrals


Citing practice losses is becoming the leading economic indicator of compensation exceeding FMV in recent enforcement cases




















Primer on Statistics

Inferential statistics

- Sample of a population is analyzed
- Characteristics of sample are extrapolated to the population: sample reflects the population
- Requires a representative sample of the population
- Requires randomized or other sampling techniques to provide for a representative sample

Descriptive statistics

- Description of a given data set
- Presents analysis of a given data
- Sample not developed as an "academic, statistically significant" representation of a population



Primer on Statistics


Surveys are a description of a nonrandom sample of U.S. physicians

- Voluntary participation
- Trade associations or client relationships
- Concentrations in characteristics of respondents
- Large multispecialty groups and health system practices
- MGMA provides filters for reporting data based on specific characteristics
- Implications for using survey data
- Not based on randomized or representative sampling methods
- Not an "academic, statistically significant" representation of the U.S. physician marketplace
- Provides a broad picture of the range of compensation and production for responding physicians who are a part of the U.S. physician market
- Requires informed use and judgment in making inferences and conclusions about specific physicians relative to survey data







ANKURA





Implications of Survey Sample Analysis Limits "truth claims" made based solely on survey data - Survey percentiles as US marketplace benchmarks - Ranges of compensation and production may be different - Patterns and relationships between compensation and production may be different - Limitations in making inferences about all US markets, local markets, and specific physicians - Characteristic trends - Alternative payment model trends Improper usage leads to an inaccurate market analysis - Misinformed FMV or CR analysis based on <u>only</u> survey trends


Surve	y Data Tab	les								
Total Compensation	n									
Specialty	10th %tile	25th %tile	Median	75th %tile	90th %tile					
Cardiology: Electrophysiology	\$350,449	\$429,826	\$541,271	\$684,299	\$814,66	57				
Cardiology: Invasive	\$297,040	\$392,511	\$484,485	\$624,697	\$770,67	4				
Cardiology: Invasive- Interventional	\$349,742	\$455,449	\$560,000	\$686,310	\$854,65	1				
Cardiology: Noninvasive	\$252,000	\$338,036	\$426,295	\$533,818	\$636,98	2				
	Work RVUs									
	Specialty Electrophysiology	10th %t	5,110 25t	th %tile Me	dian 751 ວ,ວອບ	th %tile	90th %tile 14,019			
	Cardiology: Invasive		4,113	5,937	7,946	9,693	12,533			
	Cardiology: Invasive- Interventional		5,181	6,742	8,680	11,464	14,723			
	Cardiology: Noninvasiv	e	3,840	5,274	7,070	9,212	12,020			
		Cor	mpensation	to Work RVUs F	Ratio					
		Elect	Specialty rophysiology	10th %tile	25th %1	tile Mo	edian 75t	h %tile \$/5.95	90th %tile S98.05	
			iology: Invasive	\$3	7.19	\$50.26	\$59.73	\$74.33	\$111.06	
		Cardi	iology: Invasive- ventional	\$3	9.28	\$49.86	\$60.79	\$79.92	\$98.87	
Source: MGMA DataD	ive Provider Compensation	2013 Card	iology: Noninvasive	\$3	6.12	\$46.45	\$60.30	\$79.82	\$101.97	





























ANKURA SULT

The Reality of the Data


Wide dispersion of compensation levels relative to production

- Wide range of compensation per wRVU at any given level of production
- · Median compensation rate varies by level of production
- Percentile matching is not supported by the data
- · Selecting percentiles as universal rates of FMV does not comport with the dispersion of the data
- Most newly hired physicians don't make the median total compensation as a starting salary
- wRVU production does not explain or predict the majority of total compensation for all respondents without appropriate parameters in place
- May explain more for certain subgroups



The Reality of the Data Factors driving wide dispersion of compensation levels relative to production • Local market commercial payer rates Payer mix Service mix Ancillaries Nonproduction services: call coverage, administrative • Profits on nonphysician providers Cost efficiency Ignoring these other factors in using survey data can lead to *practice losses* MGNA ANKURA CONSULTING

32



Avoid Common Misuses of MGMA Data

Inappropriate use of MGMA Data includes:

- Using total compensation as a benchmark, and adding on-call, incentives, etc. on top
- Defaulting to high percentile benchmarks when not appropriate to the situation
- Not applying data filters when applicable
- Dividing across tables to get ratios
- Matching productivity percentiles to ratio percentiles
- Using total compensation for newly hired physicians





Best Practices for Survey Usage

Remember to:

- Pay attention to survey data definitions
- Use survey data as a guide, and use multiple sources
- Use the median as the central point of a dataset; not the mean/average
- Start with current practice realities and level-set physician expectations
- Apply necessary filters to specific scenarios
- Utilize the Pay to Production Plotter and Quartile Tool for both data applications and education
- If in doubt, contact Data Solutions for data clarification



FMV Usage and Solutions

Valuation is not based on prescribed formulas

- IRS Revenue Ruling 59-60 (influential valuation text)
- "No formula can be devised that will be generally applicable to the multitude of different valuation issues..." (§ 3.01)
- "Because valuations cannot be made on the basis of a prescribed formula . . . " (§ 7)

Key to the market approach is comparability of the subject to the market data

- Comparable services
- Comparable conditions and markets
- Independent parties (without referral relationships)

Comparability of survey data

- Respondent characteristics
- Definitions of reported metrics





ANKURA

FMV Usage and Solutions Benchmarking and robust multifactor economic analysis to evaluate comparability • Multiple metrics: production, revenue, cost • Physician compensation is not singularly determined by wRVUs • Multiple factors affect physician compensation and economics of physician practices • Every physician and practice is not supposed to be at the median • by definition, most will not be! • The median is neither a floor nor a ceiling! • High or low benchmarking in and of itself is not determinative of operational or compliance issues • Do you understand the key economic drivers of the subject physician's practice relative to survey data? • Do you know why your health system's practices lose money? • Rigorous economic analysis is needed

FMV Usage and Solutions

Standard appraisal methodology

- Consideration of three approaches to value
- But, current healthcare compensation valuation practice ignores the cost and income approaches
- Outside of healthcare, the rest of the valuation world uses market data along with the cost and income approaches
- See IRS Reasonable Compensation Job Aid
- Value of professional services = net earnings generated
- Tax court cases using the independent investor test

Use the cost and income approaches too

- Earnings-based compensation with adjustments
- RBRVS model every dollar collected has a job
- Proportion for work = physician comp and benefits
- Proportion for practice expense + malpractice = overhead
- It's CMS' own payment allocation methodology!





